Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G, Vermeire S, Ferrante M.

Gut. 2018 Jul 14. pii: gutjnl-2018-316845. doi: 10.1136/gutjnl-2018-316845. [Epub ahead of print] No abstract available.

PMID:
30007919
2.

Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease.

Burisch J, Gisbert JP, Siegmund B, Bettenworth D, Thomsen SB, Cleynen I, Cremer A, Ding NJS, Furfaro F, Galanopoulos M, Grunert PC, Hanzel J, Ivanovski TK, Krustins E, Noor N, O'Morain N, Rodríguez-Lago I, Scharl M, Tua J, Uzzan M, Ali Yassin N, Baert F, Langholz E.

J Crohns Colitis. 2018 Apr 27;12(5):532-537. doi: 10.1093/ecco-jcc/jjy015.

PMID:
29415255
3.

Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease.

Vanhove W, Nys K, Arijs I, Cleynen I, Noben M, De Schepper S, Van Assche G, Ferrante M, Vermeire S.

J Crohns Colitis. 2018 Jan 24;12(2):178-187. doi: 10.1093/ecco-jcc/jjx122.

PMID:
29029005
4.

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model.

Bossuyt P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D'Hoore A, Vermeire S.

J Crohns Colitis. 2018 Jan 5;12(1):32-38. doi: 10.1093/ecco-jcc/jjx110.

PMID:
28981768
5.

Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.

Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I, Cleynen I.

Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.

PMID:
28885228
6.

Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M, Deffontaine V, Dmitrieva J, Docampo E, Elansary M, Farh KK, Franke A, Gori AS, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrance IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ; International Inflammatory Bowel Disease Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern DPB, Cho JH, Georges M, Daly MJ, Barrett JC.

Nature. 2017 Jul 13;547(7662):173-178. doi: 10.1038/nature22969. Epub 2017 Jun 28.

7.

Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.

Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S.

Scand J Gastroenterol. 2017 Oct;52(10):1086-1092. doi: 10.1080/00365521.2017.1339825. Epub 2017 Jun 16.

PMID:
28622097
8.

Genetics of inflammatory bowel disease: beyond NOD2.

Mirkov MU, Verstockt B, Cleynen I.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):224-234. doi: 10.1016/S2468-1253(16)30111-X. Epub 2017 Feb 9. Review.

PMID:
28404137
9.

RISK stratification in paediatric Crohn's disease.

Arijs I, Cleynen I.

Lancet. 2017 Apr 29;389(10080):1672-1674. doi: 10.1016/S0140-6736(17)30634-7. Epub 2017 Mar 2. No abstract available.

PMID:
28259485
10.

Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.

Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S.

Gut. 2018 Jan;67(1):43-52. doi: 10.1136/gutjnl-2016-312293. Epub 2016 Oct 7.

PMID:
27802155
11.

Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience.

Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S.

Aliment Pharmacol Ther. 2016 Oct;44(7):673-83. doi: 10.1111/apt.13754. Epub 2016 Aug 9.

12.

A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.

Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, Van Assche G, Gils A, Vermeire S.

Am J Gastroenterol. 2016 Oct;111(10):1438-1445. doi: 10.1038/ajg.2016.306. Epub 2016 Aug 2.

PMID:
27481307
13.

Genetic Influences on the Development of Fibrosis in Crohn's Disease.

Verstockt B, Cleynen I.

Front Med (Lausanne). 2016 May 30;3:24. doi: 10.3389/fmed.2016.00024. eCollection 2016. Review.

14.

Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.

Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S.

Ann Intern Med. 2016 Jan 5;164(1):10-22. doi: 10.7326/M15-0729. Epub 2015 Dec 8.

PMID:
26641955
15.

Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease.

Cleynen I, Konings P, Robberecht C, Laukens D, Amininejad L, Théâtre E, Machiels K, Arijs I, Rutgeerts P, Louis E, Franchimont D, De Vos M, Van Steen K, Georges M, Moreau Y, Vermeesch J, Vermeire S.

Inflamm Bowel Dis. 2016 Mar;22(3):505-15. doi: 10.1097/MIB.0000000000000623.

PMID:
26595553
16.

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC; International Inflammatory Bowel Disease Genetics Consortium, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW.

Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1. Epub 2015 Oct 18.

17.

The genetic architecture of inflammatory bowel disease: past, present and future.

Cleynen I, Vermeire S.

Curr Opin Gastroenterol. 2015 Nov;31(6):456-63. doi: 10.1097/MOG.0000000000000215. Review.

PMID:
26444824
18.

A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.

Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S.

J Crohns Colitis. 2015 Dec;9(12):1120-6. doi: 10.1093/ecco-jcc/jjv156. Epub 2015 Sep 7.

PMID:
26351386
19.

Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease.

Vanhove W, Peeters PM, Staelens D, Schraenen A, Van der Goten J, Cleynen I, De Schepper S, Van Lommel L, Reynaert NL, Schuit F, Van Assche G, Ferrante M, De Hertogh G, Wouters EF, Rutgeerts P, Vermeire S, Nys K, Arijs I.

Inflamm Bowel Dis. 2015 Nov;21(11):2673-82. doi: 10.1097/MIB.0000000000000535.

PMID:
26313692
20.

Immunogenicity to infliximab is associated with HLA-DRB1.

Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S.

Gut. 2015 Aug;64(8):1344-5. doi: 10.1136/gutjnl-2015-309698. Epub 2015 Apr 15. No abstract available.

PMID:
25876612
21.

Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus.

Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Castro Giner F, Peppelenbosch MP, Kovac M, Adams CL, Prenen H, Briggs S, Harrison R, Sanders S, MacDonald D, Haigh C, Tucker A, Love S, Nanji M, deCaestecker J, Ferry D, Rathbone B, Hapeshi J, Barr H, Moayyedi P, Watson P, Zietek B, Maroo N, Gay L, Underwood T, Boulter L, McMurtry H, Monk D, Patel P, Ragunath K, Al Dulaimi D, Murray I, Koss K, Veitch A, Trudgill N, Nwokolo C, Rembacken B, Atherfold P, Green E, Ang Y, Kuipers EJ, Chow W, Paterson S, Kadri S, Beales I, Grimley C, Mullins P, Beckett C, Farrant M, Dixon A, Kelly S, Johnson M, Wajed S, Dhar A, Sawyer E, Roylance R, Onstad L, Gammon MD, Corley DA, Shaheen NJ, Bird NC, Hardie LJ, Reid BJ, Ye W, Liu G, Romero Y, Bernstein L, Wu AH, Casson AG, Fitzgerald R, Whiteman DC, Risch HA, Levine DM, Vaughan TL, Verhaar AP, van den Brande J, Toxopeus EL, Spaander MC, Wijnhoven BP, van der Laan LJ, Krishnadath K, Wijmenga C, Trynka G, McManus R, Reynolds JV, O'Sullivan J, MacMathuna P, McGarrigle SA, Kelleher D, Vermeire S, Cleynen I, Bisschops R, Tomlinson I, Jankowski J.

Gastroenterology. 2015 Feb;148(2):367-78. doi: 10.1053/j.gastro.2014.10.041. Epub 2014 Nov 5.

22.

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25.

PMID:
25066841
23.

The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease.

Vanuytsel T, Vermeire S, Cleynen I.

Tissue Barriers. 2013 Dec 1;1(5):e27321. doi: 10.4161/tisb.27321. Epub 2013 Dec 10. Review.

24.

Genetic susceptibility and genotype-phenotype association in 588 Danish children with inflammatory bowel disease.

Jakobsen C, Cleynen I, Andersen PS, Vermeire S, Munkholm P, Paerregaard A, Wewer V.

J Crohns Colitis. 2014 Jul;8(7):678-85. doi: 10.1016/j.crohns.2013.12.010. Epub 2014 Jan 3.

PMID:
24394805
25.

ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behavior.

Forni D, Cleynen I, Ferrante M, Cassinotti A, Cagliani R, Ardizzone S, Vermeire S, Fichera M, Lombardini M, Maconi G, de Franchis R, Asselta R, Biasin M, Clerici M, Sironi M.

J Crohns Colitis. 2014 Jun;8(6):489-94. doi: 10.1016/j.crohns.2013.10.014. Epub 2013 Nov 21.

26.

Genetic variation in the lymphotoxin-α (LTA)/tumour necrosis factor-α (TNFα) locus as a risk factor for idiopathic achalasia.

Wouters MM, Lambrechts D, Becker J, Cleynen I, Tack J, Vigo AG, Ruiz de León A, Urcelay E, Pérez de la Serna J, Rohof W, Annese V, Latiano A, Palmieri O, Mattheisen M, Mueller M, Lang H, Fumagalli U, Laghi L, Zaninotto G, Cuomo R, Sarnelli G, Nöthen MM, Vermeire S, Knapp M, Gockel I, Schumacher J, Boeckxstaens GE.

Gut. 2014 Sep;63(9):1401-9. doi: 10.1136/gutjnl-2013-304848. Epub 2013 Nov 20.

PMID:
24259423
27.

Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress.

Hoefkens E, Nys K, John JM, Van Steen K, Arijs I, Van der Goten J, Van Assche G, Agostinis P, Rutgeerts P, Vermeire S, Cleynen I.

Autophagy. 2013 Dec;9(12):2046-55. doi: 10.4161/auto.26337. Epub 2013 Nov 14.

PMID:
24247223
28.

Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease.

Cleynen I, Vazeille E, Artieda M, Verspaget HW, Szczypiorska M, Bringer MA, Lakatos PL, Seibold F, Parnell K, Weersma RK, Mahachie John JM, Morgan-Walsh R, Staelens D, Arijs I, De Hertogh G, Müller S, Tordai A, Hommes DW, Ahmad T, Wijmenga C, Pender S, Rutgeerts P, Van Steen K, Lottaz D, Vermeire S, Darfeuille-Michaud A.

Gut. 2014 Aug;63(8):1265-74. doi: 10.1136/gutjnl-2012-303205. Epub 2013 Oct 3.

PMID:
24092863
29.

Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome.

Wouters MM, Lambrechts D, Knapp M, Cleynen I, Whorwell P, Agréus L, Dlugosz A, Schmidt PT, Halfvarson J, Simrén M, Ohlsson B, Karling P, Van Wanrooy S, Mondelaers S, Vermeire S, Lindberg G, Spiller R, Dukes G, D'Amato M, Boeckxstaens G.

Gut. 2014 Jul;63(7):1103-11. doi: 10.1136/gutjnl-2013-304570. Epub 2013 Sep 16.

PMID:
24041540
30.

An efficient algorithm to perform multiple testing in epistasis screening.

Van Lishout F, Mahachie John JM, Gusareva ES, Urrea V, Cleynen I, Théâtre E, Charloteaux B, Calle ML, Wehenkel L, Van Steen K.

BMC Bioinformatics. 2013 Apr 24;14:138. doi: 10.1186/1471-2105-14-138.

31.

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.

Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Juran BD, Milkiewicz P, Rust C, Schramm C, Müller T, Srivastava B, Dalekos G, Nöthen MM, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen CY, Croucher PJ, Sterneck M, Teufel A, Mason AL, Saarela J, Leppa V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich SS, Thompson WK, Schork AJ, Næss S, Thomsen I, Mayr G, König IR, Hveem K, Cleynen I, Gutierrez-Achury J, Ricaño-Ponce I, van Heel D, Björnsson E, Sandford RN, Durie PR, Melum E, Vatn MH, Silverberg MS, Duerr RH, Padyukov L, Brand S, Sans M, Annese V, Achkar JP, Boberg KM, Marschall HU, Chazouillères O, Bowlus CL, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M; UK-PSCSC Consortium, Rioux JD, Alexander G, Bergquist A, Cho J, Schreiber S, Manns MP, Färkkilä M, Dale AM, Chapman RW, Lazaridis KN; International PSC Study Group, Franke A, Anderson CA, Karlsen TH; International IBD Genetics Consortium.

Nat Genet. 2013 Jun;45(6):670-5. doi: 10.1038/ng.2616. Epub 2013 Apr 21.

32.

Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.

Cleynen I, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, Crusius BJ, Vecchi M, Artieda M, Szczypiorska M, Bethge J, Arteta D, Ayala E, Danese S, van Hogezand RA, Panés J, Peña SA, Lukas M, Jewell DP, Schreiber S, Vermeire S, Sans M.

Gut. 2013 Nov;62(11):1556-65. doi: 10.1136/gutjnl-2011-300777. Epub 2012 Dec 21.

PMID:
23263249
33.

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH.

Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.

34.

Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.

Perrier C, Arijs I, Staelens D, Breynaert C, Cleynen I, Covens K, Ferrante M, Van Assche G, Vermeire S, de Hertogh G, Schuit F, Rutgeerts P, Ceuppens JL.

Immunology. 2013 Jan;138(1):47-56. doi: 10.1111/imm.12014.

35.

Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

Cleynen I, Vermeire S.

Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):496-503. doi: 10.1038/nrgastro.2012.125. Epub 2012 Jul 3. Review.

PMID:
22751454
36.

Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci.

Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, Laerdahl JK, Ellinghaus D, Schramm C, Weismüller TJ, Gotthardt DN, Hov JR, Clausen OP, Weersma RK, Janse M, Boberg KM, Björnsson E, Marschall HU, Cleynen I, Rosenstiel P, Holm K, Teufel A, Rust C, Gieger C, Wichmann HE, Bergquist A, Ryu E, Ponsioen CY, Runz H, Sterneck M, Vermeire S, Beuers U, Wijmenga C, Schrumpf E, Manns MP, Lazaridis KN, Schreiber S, Baines JF, Franke A, Karlsen TH.

J Hepatol. 2012 Aug;57(2):366-75. doi: 10.1016/j.jhep.2012.03.031. Epub 2012 Apr 18.

37.

Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients.

Brinar M, Vermeire S, Cleynen I, Lemmens B, Sagaert X, Henckaerts L, Van Assche G, Geboes K, Rutgeerts P, De Hertogh G.

J Crohns Colitis. 2012 Feb;6(1):43-50. doi: 10.1016/j.crohns.2011.06.008. Epub 2011 Jul 16.

PMID:
22261526
38.

Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review.

Cleynen I, Jüni P, Bekkering GE, Nüesch E, Mendes CT, Schmied S, Wyder S, Kellen E, Villiger PM, Rutgeerts P, Vermeire S, Lottaz D.

PLoS One. 2011;6(9):e24106. doi: 10.1371/journal.pone.0024106. Epub 2011 Sep 8. Review.

39.

Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.

Márquez L, Shen C, Cleynen I, De Hertogh G, Van Steen K, Machiels K, Perrier C, Ballet V, Organe S, Ferrante M, Henckaerts L, Galicia G, Rutgeerts P, Ceuppens JL, Vermeire S.

Gut. 2012 Apr;61(4):528-34. doi: 10.1136/gut.2011.240978. Epub 2011 Jun 27.

PMID:
21708824
40.

Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease.

Henckaerts L, Cleynen I, Brinar M, John JM, Van Steen K, Rutgeerts P, Vermeire S.

Inflamm Bowel Dis. 2011 Jun;17(6):1392-7. doi: 10.1002/ibd.21486. Epub 2010 Nov 28.

PMID:
21560199
41.

Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.

Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, Ballet V, Noman M, Hoffman I, van Assche G, Rutgeerts PJ, van Steen K, Vermeire S.

Clin Gastroenterol Hepatol. 2011 May;9(5):421-7.e1. doi: 10.1016/j.cgh.2011.02.008. Epub 2011 Feb 17.

PMID:
21334460
42.

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease.

Momozawa Y, Mni M, Nakamura K, Coppieters W, Almer S, Amininejad L, Cleynen I, Colombel JF, de Rijk P, Dewit O, Finkel Y, Gassull MA, Goossens D, Laukens D, Lémann M, Libioulle C, O'Morain C, Reenaers C, Rutgeerts P, Tysk C, Zelenika D, Lathrop M, Del-Favero J, Hugot JP, de Vos M, Franchimont D, Vermeire S, Louis E, Georges M.

Nat Genet. 2011 Jan;43(1):43-7. doi: 10.1038/ng.733. Epub 2010 Dec 12.

PMID:
21151126
43.

Molecular reclassification of Crohn's disease by cluster analysis of genetic variants.

Cleynen I, Mahachie John JM, Henckaerts L, Van Moerkercke W, Rutgeerts P, Van Steen K, Vermeire S.

PLoS One. 2010 Sep 23;5(9):e12952. doi: 10.1371/journal.pone.0012952.

44.

Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity.

Brinar M, Cleynen I, Coopmans T, Van Assche G, Rutgeerts P, Vermeire S.

Gut. 2010 Dec;59(12):1728-9; author reply 1729-30. doi: 10.1136/gut.2009.194100. Epub 2010 Aug 23. No abstract available.

PMID:
20732921
45.

Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians.

Bentley RW, Cleynen I, Gearry RB, Barclay ML, Rutgeerts P, Merriman TR, Ferrante M, Roberts RL, Vermeire S.

Genes Immun. 2010 Sep;11(6):509-14. doi: 10.1038/gene.2010.15. Epub 2010 May 6.

PMID:
20445566
46.

Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.

Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P.

PLoS One. 2009 Nov 24;4(11):e7984. doi: 10.1371/journal.pone.0007984.

47.

Genetic risk profiling and prediction of disease course in Crohn's disease patients.

Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, Rutgeerts P, Vermeire S.

Clin Gastroenterol Hepatol. 2009 Sep;7(9):972-980.e2. doi: 10.1016/j.cgh.2009.05.001. Epub 2009 May 5.

PMID:
19422935
48.

Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort.

Weersma RK, Stokkers PC, Cleynen I, Wolfkamp SC, Henckaerts L, Schreiber S, Dijkstra G, Franke A, Nolte IM, Rutgeerts P, Wijmenga C, Vermeire S.

Am J Gastroenterol. 2009 Mar;104(3):630-8. doi: 10.1038/ajg.2008.112. Epub 2009 Jan 27.

PMID:
19174780
49.

The HMGA proteins: a myriad of functions (Review).

Cleynen I, Van de Ven WJ.

Int J Oncol. 2008 Feb;32(2):289-305. Review.

PMID:
18202751
50.

Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression.

Cleynen I, Huysmans C, Sasazuki T, Shirasawa S, Van de Ven W, Peeters K.

Cancer Res. 2007 May 15;67(10):4620-9.

Supplemental Content

Loading ...
Support Center